Tricor Dosage
Generic name: FENOFIBRATE 48mg
Dosage form: tablet
Drug class: Fibric acid derivatives
Medically reviewed by Drugs.com. Last updated on Jun 16, 2025.
2.1 Prior to Initiation of TRICOR
• Assess lipid levels before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, or medications) of high TG levels and manage as appropriate.
• Patients should be placed on an appropriate lipid-lowering diet before receiving TRICOR, and should continue this diet during treatment with TRICOR.
• In patients with diabetes and fasting chylomicronemia, improve glycemic control prior to considering starting TRICOR.
2.2 Recommended Dosage and Administration
• Severe hypertriglyceridemia:
○ The recommended dosage of TRICOR is 48 mg or 145 mg orally once daily.
○ Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals.
• Primary hyperlipidemia:
○ The recommended dosage of TRICOR is 145 mg orally once daily.
• Administer TRICOR as a single dose at any time of day, with or without food.
• Advise patients to swallow TRICOR tablets whole. Do not crush, break, dissolve, or chew tablets.
• Assess TG when clinically appropriate, as early as 4 to 8 weeks after initiating TRICOR. Discontinue TRICOR in patients who do not have an adequate response after 2 months of treatment.
• If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.
• Advise patients to take TRICOR at least 1 hour before or 4 hours to 6 hours after a bile acid binding resin to avoid impeding its absorption.
2.3 Recommended Dosage in Patients with Renal Impairment
• Assess renal function prior to initiation of TRICOR and periodically thereafter.
• Treatment with TRICOR should be initiated at a dosage of 48 mg orally once daily in patients with mild to moderately impaired renal function (eGFR 30 to <60 mL/min/1.73m2), and increased only after evaluation of the effects on renal function and TG levels at this dosage.
• TRICOR is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73m2), including those with end-stage renal disease (ESRD) and those receiving dialysis.
More about TriCor (fenofibrate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (16)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: fibric acid derivatives
- Breastfeeding
- En español
Patient resources
Other brands
Lofibra, Triglide, Lipofen, Antara, Fenoglide
Professional resources
Other brands
Lofibra, Triglide, Lipofen, Antara, Fenoglide
Related treatment guides
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.